REGENXBIO, Inc.

A Regenerative Medicine Powerhouse With Three Blockbuster Opportunities

About this Event

Regenxbio [NASDAQ: RGNX] is a regenerative medicine company with three assets in pivotal trials that are set to reach critical milestones this year. Regenxbio is currently targeting Hunter Syndrome, Duchenne Muscular Dystrophy, and Chronic Retinal Disease with treatments that have the potential to become standard of care in markets worth a total of $26B.

In addition to its three late-stage clinical assets, Regenxbio is differentiated from other gene therapy companies in several ways:
  • They are one of a few gene therapy companies worldwide with a cGMP facility capable of producing at commercial scale.
  • They already have partnerships in place with global pharmaceutical companies including Abbvie, Nippon Shinyaku, and Novartis.
  • Their NAV Platform technology is capable of developing broad applications across multiple disease states, creating a robust pipeline of future opportunities.
  • Their Hunter Syndrome program has received a Priority Review Voucher worth $150M.

Regenxbio has a strong balance sheet to fund operations into the second half of 2026 and multiple revenue streams currently in place including milestone payments and licensing deals.

Watch our online event with Regenxbio CFO, Mitchell Chan, and George MacDougall, Head of Investor Relations, to learn more about Regenxbio’s unique approach to gene therapy and the opportunity this is creating for investors.

Video On Demand

– Recorded

June 18

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.